Skip to main content
Melissa S. Bourque, PharmD, BCPS, BCOP

Melissa S. Bourque, PharmD, BCPS, BCOP

  • Oncology Residency Coordinator
  • Assistant Professor, The University of Tennessee Health Sciences Center, Department of Clinical Pharmacy and Translational Science

Board Certification

  • BCPS
  • BCOP


  • BS – Southeast Missouri State University, Cape Girardeau, Missouri
  • PharmD – Union University College of Pharmacy, Jackson, Tennessee

Post-Graduate Training

  • PGY1 Pharmacy Practice Residency – Mercy Hospital St. Louis and St. Louis College of Pharmacy, St. Louis, Missouri
  • PGY2 Oncology Practice Residency St. Jude Children’s Research Hospital, Memphis, Tennessee

Focused Area of Practice

  • Solid Tumor
  • Neuro Oncology
  • Pain and Palliative Care
  • Residency Training 


  • 2020   Clinical Care Improvement Award for Clinical Pharmacy Services, St. Jude Children’s Research Hospital

St. Jude Committee Service

  • Medication Use Safety Team
  • Residency Advisory Committee
  • Residency Directors’ Committee

Pharmacy Organizations/Committee Service

  • American College of Clinical Pharmacy
  • American Society of Heath-System Pharmacists
  • Children’s Oncology Group
  • Hematology Oncology Pharmacy Association
  • Pediatric Pharmacy Association
  • Tennessee Pharmacist Association

Selected Publications

Drennan CN, Pauley JL, Christensen AM, Jacobs TW, Bragg AW, Porter JS, Bourque MS. Pharmacist Effect on Discharge Follow-Up Education in Pediatric Oncology Outpatient Clinics: A Quality Improvement Study. J Pediatr Pharmacol Ther. 2023; 28(3):  262-67.

Sauer H, Crews KR, Pauley JL, Bourque MS, Bragg AW, Triplett B, Morrison RR, Hall, EA. Evaluation of Aminophylline for the Treatment of Acute Kidney Injury in Pediatric Hematology/Oncology PatientsJ Pediatr Pharmacol Ther. 2021 Jun; 26(5): 484-90.

Bourque MS, Salek M, Sabin ND, Canale M, Upadhyaya SA. Comment on: Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib [Letter to the editor].  Pediatr Blood Cancer.  2021 Apr; 68(4): e28814.

Lambrix AA, Swanson HD, Pauley JL, Bragg AW, Carias DC, Bourque MS, Zhou Y, Cheng C, Greene WL, Maron G. Experience using intravenous posaconazole in paediatric and young adult oncology patients. J Antimicrob Chemother. 2020 Dec 1;75(12): 3682-3687.

Quinn M, Fannin JT, Sciasci J, Bragg A, Campbell PK, Carias D, Crews KR, Gregornik D, Jeha S, Maron G, Pauley JL, Swanson HD, Wolf J, Greene W. Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy. Antimicrob Agents Chemother. 2018 Jul 27;62(8).

Last update: September 2023